Kiniksa Pharmaceuticals International, plc (KNSA)

Market Cap	3.06B
Revenue (ttm)	597.97M
Net Income (ttm)	35.92M
Shares Out	75.80M
EPS (ttm)	0.47
PE Ratio	86.37
Forward PE	21.50
Dividend	n/a
Ex-Dividend Date	n/a

Volume	264,852
Open	40.03
Previous Close	40.29
Day's Range	40.00 - 41.19
52-Week Range	17.82 - 42.05
Beta	0.03
Analysts	Strong Buy
Price Target	49.71 (+23.14%)
Earnings Date	Oct 28, 2025

About KNSA

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an in...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: May 24, 2018
• Employees: 315
• Stock Exchange: NASDAQ
• Ticker Symbol: KNSA
• Website: https://www.kiniksa.com

Analyst Summary

According to 7 analysts, the average rating for KNSA stock is "Strong Buy." The 12-month stock price target is $49.71, which is an increase of 23.14% from the latest price.

Price Target

$49.71

(23.14% upside)

Analyst Consensus: Strong Buy